You are using an outdated browser. Please upgrade your browser to improve your experience.

erdafitinib

Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.
Target Activities
Items per page:
10
1 – 5 of 5